Articles

This section includes the latest articles from American Pharmaceutical Review magazine. Articles featured in this section cover a wide range of topics of critical interest to the biopharm and pharmaceutical industries. From R&D strategies, meeting regulatory requirements, and new insights into manufacturing efficiencies, the articles featured here will give you the insight and knowledge needed to bring the latest medicines to market.

Filter

Hide Filter

  • Future Pharma Partner Models - Unique Delivery & Design

    Friday, July 29, 2016
    For optimal pharmacokinetics, sometimes it’s about getting the right amount of a drug to the right place at the right time. Whether a drug is delivered orally, parenterally or through some other method like ... read more

  • Future Pharma Partner Models - Next-Generation Therapies

    Friday, July 29, 2016
    Many of the most promising next generation drug products are based on biologic active pharmaceutical ingredients that require new technologies that enable their manufacture, characterization (identity, viability, ... read more

  • Roundtable

    Friday, July 29, 2016
    Process design, measurement and control for enabling continuous processing adoption in the biotech and pharmaceutical industries – the shift from batch to continuous production methods is transforming the future of ... read more

  • Sustainable Strategies For Contract Development And Manufacturing Service Growth

    Friday, July 29, 2016
    Acquisition has become a favorite tactic by contract pharma’s most prominent players, but there’s more than one path to sustained growth, especially for those seeking the scale, global presence and technical acumen ... read more

  • Innovating Equipment: Inline Buffer Dilution Technology

    Friday, July 29, 2016
    Inline buffer dilution (IBD) has been recognized as a game changer and a highly optimized solution to this critical processing step. Kimo Sanderson, Vice President of Marketing and Client Services at Asahi Kasei ... read more

  • Collaboration Is the Name of the Game

    Friday, July 29, 2016
    The rapid changes occurring in the pharmaceutical industry are placing mounting pressures on (bio) pharmaceutical companies to accomplish more with less. Outsourcing to access unique technologies, lower costs and ... read more

  • Roundtable

    Friday, July 29, 2016
    Patheon works closely with clients to develop custom solutions that are designed to meet individual needs. This requires a strategic approach and deep understanding of each client’s challenges. Some examples of this ... read more

  • Harnessing CDMO Expertise for Fill-Finish and Inspection of Sterile Pharmaceuticals

    Friday, July 29, 2016
    The 2016 Nice Insight CDMO Outsourcing Survey found that 66% and 50% of respondents’ businesses were engaged in the development of new biologic entities and biosimilars, respectively.1 Further, global spending ... read more

  • Joint Venture Contract Services – A CDMO’s Approach to Being a True Partner

    Friday, July 29, 2016
    The active pharmaceutical ingredient (API) is the key functional component of a pharmaceutical formulation, rendering efficacy to the final drug product. Driven by the aging population, public and government demands ... read more

  • COMPANY PROFILE

    Friday, July 29, 2016
    Nice Insight and the Pharma’s Almanac editorial team would like to thank all the companies participating in this quarter’s edition. The following are the profiles of the industry-leading companies that have ... read more

  • Function and Form: Advanced Pharma Packaging Design and Processing

    Friday, July 29, 2016
    Contract packaging firms that offer low cost, timeliness, flexibility and creativity, combined with assured high quality, can add real value by providing unique and differentiating solutions while allowing brand ... read more

  • Delivering on Unfulfilled Promises - Building a CDMO

    Friday, July 29, 2016
    The landscape for contract manufacturing organizations (CMOs) serving the pharmaceutical industry is changing rapidly. Most notably in 2015, the concept of contract development and manufacturing organizations (CDMOs... read more

  • Current USP Perspectives on Low Endotoxin Recovery (LER)

    Friday, July 29, 2016
    The topic of LER, or “Low Endotoxin Recovery” has dominated endotoxin discussions since 2013. What is LER? The term was coined to describe an LAL assay interference (inhibition) that was observed in an undiluted ... read more

  • Evolving Strategic Partnership Models

    Friday, July 29, 2016
    The pace and therapeutic achievements of the industry are reaching new heights not seen since the passing of the blockbuster or “Pharma 1.0” business model. Ernst & Young (EY) analysts explain that to help face ... read more

  • Removal of Endotoxin from Protein in Pharmaceutical Processes

    Friday, July 29, 2016
    Bacterial endotoxin is the lipopolysaccharide component of the cell wall of Gram-negative bacteria, together with other cellular material that combines to form an endotoxin complex. Endotoxin is pyrogenic and it ... read more
Page